Idexx Laboratories and Zoetis are leading animal health companies, but Idexx shows stronger performance due to superior capital efficiency and recurring revenue growth, especially in diagnostics. Zoetis trades at a lower valuation with solid margins but needs new catalysts for a rerating in 2026. Both companies are rated as long-term buys: Zoetis for value and income, and Idexx as a high-growth compounder, though investors might wait for a better entry point for Idexx. This comparison highlights their different strengths and investment profiles in the growing animal health market.
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
